{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T21:30:07Z","timestamp":1791495007308,"version":"4.3.4"},"reference-count":53,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,12,11]],"date-time":"2023-12-11T00:00:00Z","timestamp":1702252800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003042","name":"Else Kr\u00f6ner-Fresenius-Stiftung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003042","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Plaque psoriasis is an autoinflammatory and autoimmune skin disease, affecting 1-3% of the population worldwide. Previously, high levels of IL-36 family cytokines were found in psoriatic skin lesions, thereby contributing to keratinocyte hyperproliferation and infiltration of immune cells such as neutrophils. While treatment with anti-IL36 receptor (IL36R) antibodies was recently approved for generalized pustular psoriasis (GPP), it remains unclear, if targeting the IL36R might also inhibit plaque psoriasis. Here we show that antibody-mediated inhibition of IL36R is sufficient to suppress imiquimod-induced psoriasis-like skin inflammation and represses the disease\u2019s development in a model that depends on IL-17A overexpression in the skin. Importantly, treatment with anti-IL36R antibodies inhibited skin inflammation and attenuated psoriasis-associated, systemic inflammation. This is possibly due to a widespread effect of IL36R inhibition, which not only suppresses pro-inflammatory gene expression in keratinocytes, but also the activation of other immune cells such as T-cells or dendritic cells. In conclusion, we propose that inhibition of the IL-36 signaling pathway might constitute an attractive, alternative approach for treating IL-17A-driven psoriasis and psoriasis-linked comorbidities.<\/jats:p>","DOI":"10.3389\/fimmu.2023.1256133","type":"journal-article","created":{"date-parts":[[2023,12,11]],"date-time":"2023-12-11T06:30:20Z","timestamp":1702276220000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":24,"title":["IL-17A-driven psoriasis is critically dependent on IL-36 signaling"],"prefix":"10.3389","volume":"14","author":[{"given":"Berenice","family":"Fischer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja","family":"K\u00fcbelbeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Kolb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Ringen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ari","family":"Waisman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Wittmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Karbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan Marcus","family":"K\u00f6lsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,12,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-032713-120225","article-title":"Immunology of psoriasis","volume":"32","author":"Lowes","year":"2014","journal-title":"Annu Rev Immunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, clinical presentation, and treatment of psoriasis: A review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2014.532","article-title":"IL-36 gamma (IL-1F9) is a biomarker for psoriasis skin lesions","volume":"135","author":"D'Erme","year":"2015","journal-title":"J Invest Dermatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12761","article-title":"Distinct expression of interleukin (IL)-36alpha, beta and gamma, their antagonist IL-36Ra and IL-38 in psoriasis, rheumatoid arthritis and crohn's disease","volume":"184","author":"Boutet","year":"2016","journal-title":"Clin Exp Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M400117200","article-title":"Interleukin (IL)-1F6, IL-1F8, and IL-1F9 signal through IL-1Rrp2 and IL-1RAcP to activate the pathway leading to NF-kappaB and MAPKs","volume":"279","author":"Towne","year":"2004","journal-title":"J Biol Chem"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M111.267922","article-title":"Interleukin-36 (IL-36) ligands require processing for full agonist (IL-36alpha, IL-36beta, and IL-36gamma) or antagonist (IL-36Ra) activity","volume":"286","author":"Towne","year":"2011","journal-title":"J Biol Chem"},{"key":"B7","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/j.jaci.2018.04.031","article-title":"Detection of IL-36gamma through noninvasive tape stripping reliably discriminates psoriasis from atopic eczema","volume":"142","author":"Berekmeri","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2015.12.072","article-title":"Neutrophil-derived proteases escalate inflammation through activation of IL-36 family cytokines","volume":"14","author":"Henry","year":"2016","journal-title":"Cell Rep"},{"key":"B9","doi-asserted-by":"publisher","first-page":"108515","DOI":"10.1016\/j.celrep.2020.108515","article-title":"The proinflammatory cytokine IL-36gamma is a global discriminator of harmless microbes and invasive pathogens within epithelial tissues","volume":"33","author":"Macleod","year":"2020","journal-title":"Cell Rep"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12610","article-title":"Regulation and function of interleukin-36 cytokines","volume":"281","author":"Bassoy","year":"2018","journal-title":"Immunol Rev"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1801377115","article-title":"IkappaBzeta is a key transcriptional regulator of IL-36-driven psoriasis-related gene expression in keratinocytes","volume":"115","author":"Muller","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-05-356873","article-title":"IL-36R ligands are potent regulators of dendritic and t cells","volume":"118","author":"Vigne","year":"2011","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/exd.13228","article-title":"IL-36gamma has proinflammatory effects on human endothelial cells","volume":"26","author":"Bridgewood","year":"2017","journal-title":"Exp Dermatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0222969","article-title":"Interleukin (IL)-17\/IL-36 axis participates to the crosstalk between endothelial cells and keratinocytes during inflammatory skin responses","volume":"15","author":"Mercurio","year":"2020","journal-title":"PloS One"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-06-439026","article-title":"IL-36 signaling amplifies Th1 responses by enhancing proliferation and Th1 polarization of naive CD4+ t cells","volume":"120","author":"Vigne","year":"2012","journal-title":"Blood"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1301481","article-title":"IL-36 promotes myeloid cell infiltration, activation, and inflammatory activity in skin","volume":"192","author":"Foster","year":"2014","journal-title":"J Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2023.01.003","article-title":"IL-36gamma augments ocular angiogenesis by promoting the vascular endothelial growth factor-vascular endothelial growth factor receptor axis","volume":"193","author":"Cho","year":"2023","journal-title":"Am J Pathol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.ccell.2015.07.014","article-title":"IL-36gamma transforms the tumor microenvironment and promotes type 1 lymphocyte-mediated antitumor immune responses","volume":"28","author":"Wang","year":"2015","journal-title":"Cancer Cell"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.09.035","article-title":"Pustular psoriasis: Molecular pathways and effects of spesolimab in generalized pustular psoriasis","volume":"149","author":"Baum","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01801-4","article-title":"Spesolimab: First approval","volume":"82","author":"Blair","year":"2022","journal-title":"Drugs"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1172\/JCI63451","article-title":"Psoriasiform dermatitis is driven by IL-36-mediated DC-keratinocyte crosstalk","volume":"122","author":"Tortola","year":"2012","journal-title":"J Clin Invest."},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.26508\/lsa.201900586","article-title":"Keratinocyte interleukin-36 receptor expression orchestrates psoriasiform inflammation in mice","volume":"3","author":"Hernandez-Santana","year":"2020","journal-title":"Life Sci Alliance."},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.26508\/lsa.202000688","article-title":"IL-36 signaling in keratinocytes controls early IL-23 production in psoriasis-like dermatitis","volume":"3","author":"Goldstein","year":"2020","journal-title":"Life Sci Alliance."},{"key":"B24","doi-asserted-by":"publisher","first-page":"15631","DOI":"10.1038\/s41598-017-15892-7","article-title":"The psoriasis-associated IL-17A induces and cooperates with IL-36 cytokines to control keratinocyte differentiation and function","volume":"7","author":"Pfaff","year":"2017","journal-title":"Sci Rep"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2021.01.019","article-title":"IL-36 and IL-17A cooperatively induce a psoriasis-like gene expression response in human keratinocytes","volume":"141","author":"Miura","year":"2021","journal-title":"J Invest Dermatol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00200","article-title":"IL-36gamma is a strong inducer of IL-23 in psoriatic cells and activates angiogenesis","volume":"9","author":"Bridgewood","year":"2018","journal-title":"Front Immunol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/ng.311","article-title":"Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways","volume":"41","author":"Nair","year":"2009","journal-title":"Nat Genet"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2016.09.015","article-title":"Shrinking the psoriasis assessment gap: Early gene-expression profiling accurately predicts response to long-term treatment","volume":"137","author":"Correa da Rosa","year":"2017","journal-title":"J Invest Dermatol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2012.184","article-title":"Expanding the psoriasis disease profile: interrogation of the skin and serum of patients with moderate-to-severe psoriasis","volume":"132","author":"Suarez-Farinas","year":"2012","journal-title":"J Invest Dermatol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2017.1353853","article-title":"Generation and functional characterization of anti-human and anti-mouse IL-36R antagonist monoclonal antibodies","volume":"9","author":"Ganesan","year":"2017","journal-title":"MAbs"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aax1686","article-title":"Enhanced IL-36R signaling promotes barrier impairment and inflammation in skin and intestine","volume":"5","author":"Hovhannisyan","year":"2020","journal-title":"Sci Immunol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"9089","DOI":"10.1038\/s41598-019-45626-w","article-title":"Small molecule IL-36gamma antagonist as a novel therapeutic approach for plaque psoriasis","volume":"9","author":"Todorovic","year":"2019","journal-title":"Sci Rep"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2013.404","article-title":"IL-6 regulates neutrophil microabscess formation in IL-17A-driven psoriasiform lesions","volume":"134","author":"Croxford","year":"2014","journal-title":"J Invest Dermatol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.130835","article-title":"Keratinocyte-derived IkappaBzeta drives psoriasis and associated systemic inflammation","volume":"4","author":"Lorscheid","year":"2019","journal-title":"JCI Insight"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.114.304108","article-title":"Interleukin 17 drives vascular inflammation, endothelial dysfunction, and arterial hypertension in psoriasis-like skin disease","volume":"34","author":"Karbach","year":"2014","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1111\/exd.13841","article-title":"IL-36 receptor antagonistic antibodies inhibit inflammatory responses in preclinical models of psoriasiform dermatitis","volume":"28","author":"Su","year":"2019","journal-title":"Exp Dermatol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12865-021-00401-3","article-title":"Application of imiquimod-induced murine psoriasis model in evaluating interleukin-17A antagonist","volume":"22","author":"Li","year":"2021","journal-title":"BMC Immunol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ejphar.2018.03.018","article-title":"Anti-IL-12\/IL-23p40 antibody ameliorates dermatitis and skin barrier dysfunction in mice with imiquimod-induced psoriasis-like dermatitis","volume":"828","author":"Takahashi","year":"2018","journal-title":"Eur J Pharmacol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/s41419-022-04523-3","article-title":"Advances in the pathogenesis of psoriasis: from keratinocyte perspective","volume":"13","author":"Zhou","year":"2022","journal-title":"Cell Death Dis"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2016.10.024","article-title":"The snowballing literature on imiquimod-induced skin inflammation in mice: A critical appraisal","volume":"137","author":"Hawkes","year":"2017","journal-title":"J Invest Dermatol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1016\/j.jaci.2017.07.045","article-title":"Toll-like receptor 7\/8 agonists stimulate plasmacytoid dendritic cells to initiate T(H)17-deviated acute contact dermatitis in human subjects","volume":"141","author":"Garzorz-Stark","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/j.jid.2022.10.017","article-title":"Cathelicidin antimicrobial peptide LL37 induces toll-like receptor 8 and amplifies IL-36gamma and IL-17C in human keratinocytes","volume":"143","author":"Miura","year":"2023","journal-title":"J Invest Dermatol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.905239","article-title":"Comparative analysis of single-cell transcriptome data reveals a novel role of keratinocyte-derived IL-23 in psoriasis","volume":"13","author":"Park","year":"2022","journal-title":"Front Immunol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"3455","DOI":"10.1038\/s41467-023-39020-4","article-title":"Single cell and spatial sequencing define processes by which keratinocytes and fibroblasts amplify inflammatory responses in psoriasis","volume":"14","author":"Ma","year":"2023","journal-title":"Nat Commun"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2019.04.029","article-title":"IL-17A inhibition by secukinumab induces early clinical, histopathologic, and molecular resolution of psoriasis","volume":"144","author":"Krueger","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.11.042","article-title":"Psoriatic skin molecular and histopathologic profiles after treatment with risankizumab versus ustekinumab","volume":"143","author":"Visvanathan","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2015-310374","article-title":"IL-36R signalling activates intestinal epithelial cells and fibroblasts and promotes mucosal healing in vivo","volume":"66","author":"Scheibe","year":"2017","journal-title":"Gut"},{"key":"B48","doi-asserted-by":"publisher","first-page":"4003","DOI":"10.1038\/s41467-019-11944-w","article-title":"Interleukin-36 cytokines alter the intestinal microbiome and can protect against obesity and metabolic dysfunction","volume":"10","author":"Giannoudaki","year":"2019","journal-title":"Nat Commun"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.155236","article-title":"Targeting IL-36 improves age-related coronary microcirculatory dysfunction and attenuates myocardial ischemia\/reperfusion injury in mice","volume":"7","author":"El-Awaisi","year":"2022","journal-title":"JCI Insight"},{"key":"B50","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/s41385-022-00488-w","article-title":"IL-36 cytokines imprint a colitogenic phenotype on CD4(+) t helper cells","volume":"15","author":"Leon","year":"2022","journal-title":"Mucosal Immunol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1172\/JCI134217","article-title":"The CDK4\/6-EZH2 pathway is a potential therapeutic target for psoriasis","volume":"130","author":"Muller","year":"2020","journal-title":"J Clin Invest."},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.freeradbiomed.2003.10.012","article-title":"Measurement of NAD(P)H oxidase-derived superoxide with the luminol analogue l-012","volume":"36","author":"Daiber","year":"2004","journal-title":"Free Radic Biol Med"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000239207.82326.29","article-title":"Nebivolol inhibits superoxide formation by NADPH oxidase and endothelial dysfunction in angiotensin II-treated rats","volume":"48","author":"Oelze","year":"2006","journal-title":"Hypertension"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1256133\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,11]],"date-time":"2023-12-11T06:30:24Z","timestamp":1702276224000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1256133\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,11]]},"references-count":53,"alternative-id":["10.3389\/fimmu.2023.1256133"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1256133","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,11]]},"article-number":"1256133"}}